Plasma-Derived IgG Enrichment via Cation Exchange Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing plasma-derived immunoglobulin G (IgG) compositions enriched in anti-brain disease-related antibodies, such as anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies, disrupt existing manufacturing processes and require regulatory re-approval, making them impractical for large-scale production.
Innovation Solution
A method involving cation exchange chromatography is used to isolate these antibodies by binding IgG to a cation exchange material, eluting the bulk IgG with a first buffer, and then using a second buffer to elute the remaining bound IgG, resulting in an eluate enriched in anti-brain disease-related antibodies, without altering the existing manufacturing processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing methods for producing plasma-derived IgG compositions enriched in anti-brain disease-related antibodies are implemented, then the titer of anti-brain disease-related antibodies is increased, but the manufacturing process is disrupted and regulatory re-approval is required
Solution Approach 1:
The patent extracts only the necessary enrichment step (cation exchange chromatography with specific elution conditions) from the existing manufacturing process. This allows the enrichment of anti-brain disease-related antibodies to be performed as a separate, optional step that does not require complete process re-validation, thereby increasing antibody titer while minimizing manufacturing disruption
Solution Approach 2:
The patent changes specific parameters of the cation exchange chromatography process (elution buffer pH, conductivity ranges, elution step timing) to achieve selective enrichment of anti-brain disease-related antibodies. By optimizing these parameters, the method achieves high antibody titers while maintaining compatibility with existing manufacturing frameworks
2Quantity of substance
If cation exchange chromatography is used to enrich anti-brain disease-related antibodies, then the concentration of specific antibodies is increased up to 95-fold, but the device complexity and process steps are increased
Solution Approach 1:
The patent uses a universal cation exchange chromatography approach that can be applied to existing plasma-derived IgG manufacturing processes. The same chromatography platform and resins used in current manufacturing are leveraged, adding enrichment capability without requiring entirely new equipment or complex process integration
Solution Approach 2:
The enrichment process is segmented into distinct, manageable steps (binding, washing with controlled conductivity, selective elution) that can be independently optimized and integrated into existing manufacturing workflows. This segmentation reduces overall process complexity while achieving high antibody concentration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces plasma-derived IgG compositions with significantly higher titers of anti-brain disease-related antibodies, up to 65- to 95-fold higher for anti-Aβ, 20-fold for anti-RAGE, and 50-fold for anti-α-synuclein, while maintaining the integrity of the manufacturing process and regulatory compliance.
Implementation Method 1
binding IgG to a cation exchange material
Data Source
AI summary
The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), are also provided.